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FORUM REVIEW ARTICLE
Oxidative Stress and Chromatin Remodeling
in Chronic Obstructive Pulmonary Disease
and Smoking-Related Diseases
Isaac K. Sundar, Hongwei Yao, and Irfan Rahman
Abstract
Significance: Chronic obstructive pulmonary disease (COPD) is predominantly a tobacco smoke-triggered dis-
ease with features of chronic low-grade systemic inflammation and aging (inflammaging) of the lung associated
with steroid resistance induced by cigarette smoke (CS)-mediated oxidative stress. Oxidative stress induces
various kinase signaling pathways leading to chromatin modifications (histone acetylation/deacetylation and
histone methylation/demethylation) in inflammation, senescence, and steroid resistance. Recent Advances:
Histone mono-, di-, or tri-methylation at lysine residues result in either gene activation (H3K4, H3K36, and
H3K79) or repression (H3K9, H3K27, and H3K20). Cross-talk occurs between various epigenetic marks on
histones and DNA methylation. Both CS and oxidants alter histone acetylation/deacetylation and methylation/
demethylation leading to enhanced proinflammatory gene expression. Chromatin modifications occur in lungs
of patients with COPD. Histone deacetylase 2 (HDAC2) reduction (levels and activity) is associated with steroid
resistance in response to oxidative stress. Critical Issues: Histone modifications are associated with DNA
damage/repair and epigenomic instability as well as premature lung aging, which have implications in the
pathogenesis of COPD. HDAC2/SIRTUIN1 (SIRT1)-dependent chromatin modifications are associated with
DNA damage-induced inflammation and senescence in response to CS-mediated oxidative stress. Future
Directions: Understanding CS/oxidative stress-mediated chromatin modifications and the cross-talk between
histone acetylation and methylation will demonstrate the involvement of epigenetic regulation of chromatin
remodeling in inflammaging. This will lead to identification of novel epigenetic-based therapies against COPD
and other smoking-related lung diseases. Pharmacological activation of HDAC2/SIRT1 or reversal of their
oxidative post-translational modifications may offer therapies for treatment of COPD and CS-related diseases
based on epigenetic histone modifications. Antioxid. Redox Signal. 18, 1956–1971.
Introduction
Lung cells are constantly exposed to a variety of oxi-dants, either generated endogenously due to metabolic
activity (mitochondrial electron transport during respiration,
upon activation of phagocytes), or exogenously through cig-
arette smoke (CS), air pollutants, and noxious gases (119, 124).
The lung is a direct target for oxidative injury from reactive
oxygen species (ROS) and free radicals. Oxidative stress
results in increased cellular signaling associated with post-
translational modifications of histones and nonhistone pro-
teins, and redox modifications of proteins implicated in
chromatin remodeling (48, 152, 179, 181) (Fig. 1).
DNA is packed into chromatin by histones to form a tightly
coiled structure in the nucleus. Chromatin remodeling by his-
tone modifications plays a key role in the regulation of cellular
processes, including gene transcription/repression, DNA
repair, differentiation, and proliferation. Post-translational
histone modifications predominantly occur via acetylation/
deacetylation and methylation/demethylation reactions (41,
127) (Fig. 1).
Histone acetyltransferases (HATs, including p300- CREB-
binding protein [CBP]-associated factor, p300/CBP, and
GCN5) and histone deacetylases (HDACs e.g., HDAC2 and
SIRTUIN1 [SIRT1]) maintain the balance between histone
acetylation and deacetylation. HATs affect the binding of
DNA sequence-specific transcription factors and, subse-
quently, recruit coactivators or corepressors on gene-specific
regions to form either coactivator or corepressor complexes
(166). It is well known that transcriptional coactivators
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possess intrinsic HAT (CBP/p300) and HDAC activities,
suggesting that histone acetylation and deacetylation play a
causal role in regulating gene transcription (72, 170, 171). It is
generally accepted that increase in histone acetylation leads to
increased gene transcription, while histone hypoacetylation is
linked to decreased gene transcription (72, 170, 171). Histone
acetylation by HATs and deacetylation by HDACs are also
linked to cell-cycle progression, proliferation, senescence,
DNA repair, and recombination events, as well as proin-
flammatory gene transcription, which can be affected by
oxidative stress and redox signaling (15, 69, 146).
Methylation of histones occurs either on lysine (K) or ar-
ginine (R) residues in a reaction that is catalyzed by specific
histone methyltransferases (HMTs) (11, 192). HMTs utilize
S-adenosylmethionine as a cofactor during transmethylation
and produce S-adenosylhomocysteine as a by-product. Me-
thylation of specific lysine residues results in the formation of
binding sites/interacting domains, which allow recruitment
of other regulator proteins. HMTs are deregulated in several
chronic lung diseases, thereby affecting the global methyla-
tion status. Histone demethylases (HDMs) catalyze the re-
moval of methyl groups from lysine or arginine residue of
histones. These include lysine-specific demethylase 1 and Ju-
monji C domain family proteins involved in the regulation of
gene expression (149). These enzymes demethylate specific
histone residues, thereby forming transcriptional repression
complexes (133). HMTs and HDMs are subject to redox reg-
ulation such that post-translational modifications of histone
proteins by oxidants and environmental stresses can trigger
the transcription of genes that are involved in chronic in-
flammatory events. This review is focused on the role of ROS-
mediated effects on chromatin modification enzymes and
epigenetic chromatin modifications (histone acetylation/
deacetylation and histone methylation/demethylation) in
inflammatory response, steroid resistance, and cellular se-
nescence that occurs in chronic inflammatory lung diseases
associated with cigarette/tobacco smoking.
Cigarette Smoke and Oxidative Stress
ROS can affect the lung by directly oxidizing proteins,
DNA, and lipids or induce changes indirectly through the
generation of secondary metabolic reactive species. ROS can
fragment the extracellular matrix, and cause mucus secretion,
apoptosis, and alter cell proliferation (113). Relevant ROS
generating enzyme systems in Chronic Obstructive Pulmon-
ary Disease (COPD) include xanthine–xanthine oxidase,
NADPH oxidase, and heme peroxidases (108, 117). CS, which
contains 1015 free radicals and 4700 different chemical com-
pounds per puff, is the major source of inhaled environmen-
tally derived ROS. It has been estimated that 15%–20% of
smokers develop COPD. The Global Initiative for Chronic
Obstructive Lung Disease defines COPD as a syndrome of
chronic, irreversible obstruction of lung airflow characterized
by progressive decline in forced expiratory volume in one
second. The inflammatory immune features of the COPD
phenotype includes, activation of epithelial cells, and resident
macrophages, as well as the recruitment and activation of
neutrophils, monocytes and B and T lymphocytes into the
lung. Inflammatory cells are activated in response to cyto-
kines/chemokines/chemoattractants after recruitment into
the interstitium, thereby generating various ROS. ROS cause
lipid peroxidation (oxidation of membrane phospholipids)
and the generation ofmalondialdehyde, 4-hydroxy-2-nonenal,
acrolein, and F2-isoprostanes (114, 120).
Oxidative Stress and Kinases Signaling
in Chromatin Remodeling
It is well known that ROS can activate signal transducing
molecules through the effects on oxidation-prone cysteine-
rich domains, thereby activating gene transcription (6, 118).
These include the mitogen-activated protein kinase family,
extracellular signal-regulated kinase, c-Jun N-terminal kinase
( JNK), p38 kinase, and phosphoinositide 3-kinase (PI3K)/
Akt. Based on the redox status of the cells, members of
the MAPK family are activated, leading to a multifaceted
transactivation of redox-sensitive transcription factors (ATF-
2, CBP) (6, 147). Furthermore, activation of upstream kinases,
such as nuclear factor-jB (NF-jB)-inducing kinase, mitogen-
and stress-activated kinase 1, and IjB kinase-a, results in
downstream chromatin remodeling events that alter the
function of various gene promoters (27, 28, 138, 179, 181). This
epigenetic mechanism modulates a series of specific proin-
flammatory gene transcription events that modulate apopto-
sis, autophagy, senescence, proliferation, transformation, and
differentiation (53). CS induces activation of protein kinase C
(PKC), mediates regulation of intracellular signaling path-
ways (174). PKCf-knockout mice exposed to CS or lipopoly-
saccharide showed a reduction in lung inflammatory
response due to chromatin modifications, suggesting that
PKCf is an important modifier of lung inflammatory response
FIG. 1. Differentially regulated chromatin modification
genes and DNA methyltransferases are involved in ciga-
rette smoke-mediated histone modifications. Unwinding
and rewinding of DNA is regulated by epigenetic alterations,
such as histone acetylation/deacetylation and histone
methylation/demethylation. This includes histone acetyla-
tion by histone acetyltransferases (HATs), histone deacety-
lation by histone deacetylases (HDACs), histone methylation
by SET domain proteins and histone methyltransferases
(HMTs), histone demethylation by histone demethylases
(HDMs), and DNA methylation by DNA methyltransferases
(DNMTs), respectively. Cigarette smoke-mediated epigenetic
changes and chromatin conformation changes can lead to
alterations in DNA accessibility for transcription factors,
coactivators, and polymerases, thereby, resulting in either
transcriptional gene activation or gene repression of proin-
flammatory genes. Some examples of histone modification
enzymes are given in parenthesis.
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(Fig. 2) (186). Hence, activation of kinases by ROS and alde-
hyde/lipid peroxidation products can lead to a proin-
flammatory response by chromatin remodeling.
The role of PI3K and p38 signaling pathways have been
shown in pathogenesis of COPD and lung cancer (34, 37, 51).
Inhibition of PI3K/p38 lowers tobacco/CS-induced lung in-
flammatory response (34). Interestingly, PI3K inhibition sig-
nificantly increased the steroid efficacy to inhibit an
inflammatory response under oxidative stress (14, 82, 151).
Therefore, in addition to p38 MAPK and PKCf, oxidants/CS-
mediated activation of the PI3K signaling pathway may be a
target for intervention in COPD. These oxidant- and redox-
sensitive pathways (PI3K/p38) activate various kinases, such
as NF-jB-inducing kinase, mitogen- and stress-activated
kinase 1, and IjB kinase-a, resulting in histone acetylation and
transcriptional activation of proinflammatory genes (e.g., IL-6,
IL-8, and COX-2) (27, 138, 179) (Fig. 2).
Chromatin Remodeling: Histone Acetylation,
Deacetylation, Methylation, and Demethylation
Histone acetyltransferases
HATs transfer acetyl groups from acetyl-CoA to the N-
terminal lysine residues of histones (H3 and H4), thereby
uncoiling DNA resulting in the transcription factor binding
to promoters followed by transcriptional gene activation
(56, 58, 119, 144). HATs and HDACs play opposing roles in
regulating acetylation of core nucleosomal histones. HATs are
classified into five distinct families. These include the CBP/
p300 HATs, Gcn5-related acetyltransferases, the general tran-
scription factor HATs (TFIID subunit TAF250), and the nuclear
hormone-related HATs SRC1 and ACTR (SRC3) (144, 153).
Each of these HAT families has diverse roles in regulating the
chromatin assembly and structure (chromatin remodeling) al-
though they share a common enzymatic activity (112).
CS/oxidant-mediated acetylation of histone H3 occurs in
macrophages and epithelial cells, and in lungs of humans and
rodents, suggesting that histone acetylation/deacetylation
plays an important role in chromatin remodeling. Oxidative
stress and/or glutathione depletion is associated with in-
creased histone acetylation (119, 120). CS-mediated alter-
ations in chromatin remodeling are shown to be involved in
sustained lung inflammatory diseases, such as COPD (83, 140,
143, 179, 186). CBP and p300 are the known coactivators that
possess intrinsic HAT activity. They are regulated by the
JNK/p38 MAP kinase pathway, which activates redox-
sensitive transcription factors, such as NF-jB and activator
protein-1 (148). Therefore, histone acetylation by CBP/p300
has an impact on the activation of specific proinflammatory
mediators linked with NF-jB/AP-1-mediated gene expres-
sion (22, 64, 115). Transcription factor NF-jB (RelA/p65) is
acetylated at K310 residue by CBP/p300HAT, but also causes
histone acetylation by recruiting other cofactors/coactivators
and chromatin remodeling complexes to activate proin-
flammatory gene transcription (e.g., IL-6 and IL-8) (46, 57, 75).
It is shown that NF-jB-induced acetylation of histone H3, but
not histone H2A, H2B, or H3, occurs in epithelial cells on
specific lysine residues (Lys8 and Lys12) at NF-jB-responsive
regulatory elements on proinflammatory genes (57). Oxida-
tive stress and CS activate NF-jB, HAT, CBP/p300 leading to
specific histone acetylation in macrophages and lung cells (60,
93, 178, 179, 187). Therefore, development of small molecules
that target for inhibition of HATs (e.g., CBP/p300, PCAF, and
GCN) may be useful for therapeutic intervention in COPD
and other chronic inflammatory lung diseases associatedwith
smoking mediated oxidative stress (8, 99).
Histone deacetylases
HDACs play a crucial role in removing the acetyl groups
from histones, thus providing a regulatory role toward the
epigenetic control of gene expression (17). Presence of HDACs
within the gene regulatory regions leads to formation of
closed chromatin complexes (heterochromatin) resulting in
gene silencing. So far, eighteen mammalian HDAC enzymes
are known, which are classified into four classes based on
their homology to a prototypical HDAC found in yeast (32)
(Fig. 3). Class I HDACs (HDACs 1, 2, 3, and 8) are ubiqui-
tously expressed with the possible exception of HDAC3 and
HDAC10, which are predominantly localized in the nucleus
(145). Class II HDACs (HDACs 4, 5, 6, 7, 9, and 10) are ex-
pressed in a tissue-specific manner, and they have the ability
to shuttle between the nucleus and cytoplasm (13, 50). The
shuttling of class II HDACs from the nucleus is mainly reg-
ulated by nuclear export signaling 14-3-3 proteins (13). Based
on the existence of tandem deacetylase domains, class II
HDACs are further classified into class IIa (HDACs, 4, 5, 7,
and 9) and class IIb (HDACs 6 and 10) (62). Class I and II
HDACs share significant homology at the deacetylase do-
main, but differ in their N-terminal sequence (Fig. 3).
FIG. 2. Role of redox kinase signaling in chromatin
modifications. Cigarette smoke-derived oxidants/aldehydes
activate several kinase signaling mechanisms, such as NIK,
IKKa, MSK1, and PKCf by redox modulation, and induce
proinflammatory gene transcription via chromatin modifi-
cations. Upon activation of these kinases, NF-jB interacts
with the master coactivator cAMP-response-element-binding
protein (CBP/p300), and causes acetylation of specific lysine
residues on core histones by displacing/decreasing histone
deacetylases, leading to gene transcription. HATs, such as
CBP/p300 and P/CAF, mediate histone acetylation (eu-
chromatin) by loosening the nucleosomes, thereby, promot-
ing access of cofactors and RNA polymerase II to mediate
active gene expression. HDACs, such as SIRT1 and HDAC2,
mediate deacetylation (heterochromatin) by tightly winding
the nucleosomes, thereby, making the DNA inaccessible to
transcription factors and other protein complexes, thus, re-
sulting in gene repression.
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The class III HDACs or sirtuins are named based on their
homology to the yeast Sir2 gene, which is a highly conserved
gene family. In humans, sirtuins comprise seven members,
SIRT 1–7 (86). Among these, SIRT1, SIRT2, SIRT3, and SIRT5
have an NAD+ -dependent deacetylase domain (distinct from
the zinc-dependent deacetylase domains of class I and II
HDACs), which catalyze the deacetylation of histones and
nonhistone proteins. Since sirtuins utilize NAD+ obtained
from metabolic processes, it plays vital roles in linking mo-
lecular mechanisms between cellular metabolic status
(NAD +/NADH levels) and several cellular processes (16). In
contrast, SIRT4 and SIRT6 have an NAD+ -dependent ADP
ribosylation domain and catalyze protein ribosylation. The
subcellular localizations of sirtuin family members are well
defined. SIRT1, SIRT6, and SIRT7 are localized to the nucleus;
SIRT2 to the cytoplasm and SIRT3, SIRT4, and SIRT5 are lo-
calized to the mitochondria. Class III HDACs share less ho-
mology compared to the class I and II HDACs, and are not
inhibited by widely used HDAC inhibitors, such as butyrate,
valproic acid, trichostatin A (TSA), or suberoylanilide hy-
droxamic acid (175) (Fig. 3). Instead, they are inhibited
by nicotinamide, splitomicin, and sirtinol. SIRT1 is a redox-
sensitive deacetylases, which requires intracellular NAD + for
its regulations (20). HDAC11 belongs to class IV HDACs,
which share limited homologywith class I and II HDACs (44).
HDACs are also reported to deacetylate nonhistone pro-
teins, such as the redox-sensitive transcription factor NF-jB
(RelA/p65) and forkhead box class O3 (FOXO3), thereby
regulating transcription of NF-jB-dependent proin-
flammatory genes (132). The levels and activities of HDACs
are significantly decreased in macrophages, and lung cells
in vitro in response to oxidative/carbonyl stress, as well as in
lungs of COPD patients via alterations in intracellular GSH/
GSSG redox ratio (caused by H2O2 and CS exposures). De-
creased HDAC2 activity is linked with COPD severity, asth-
ma, and steroid resistance in asthmatics who smoke tobacco
(5, 60, 93, 178, 187). Intracellular GSH maintains HDAC2 in a
reduced environment, and increasing intracellular GSH in-
hibits HDAC2 oxidative post-translational modifications
(5, 85, 178). A decrease in levels of HDAC2 in several cellular
systems is due to post-translational modifications, such as
oxidation/carbonylation, nitrosylation, acetylation, and
phosphorylation in response to oxidants derived from CS (3,
5, 59, 93, 178). Hence, HDAC2 levels/activities and the status
of oxidative post-translational modifications dictate the ef-
fects of coactivators on the chromatin status on various pro-
moters to drive the gene activation or repression.
HDAC2 and steroid resistance in inflammation
Decreased HDAC2 occurring as a result of CS/oxidants/
aldehydes is associated with activation of NF-jB RelA/p65
subunit (evident as increased levels of total and phospho-
acetylated RelA/p65). RelA/p65 interacts with HDAC2, and
nuclear accumulation of RelA/p65 result in transcription of
proinflammatory genes when HDAC2 is post-translationally
modified, ubiquitinated, and degraded (79, 178, 185, 187).
HDAC2 modification is dependent on the cellular thiol
(GSH/GSSG) redox status (85, 178). In vitro studies using
trichostatin A (HDAC inhibitor) in different cell lines showed
enhanced NF-jB-driven inflammatory gene transcription
(24, 57). Hence, alteration of HDACs (particularly HDAC2) by
CS/oxidative stress leads to increased acetylation of histones
(histone H3 and H4) and activation of NF-jB, thus enhancing
transcription of proinflammatory genes (4, 123, 178). In
humans, a marked reduction of HDAC2 expression/activity
in lung parenchyma, bronchial biopsies, and alveolar mac-
rophages of patients with COPD is correlated with the se-
verity of inflammation and the progression of the disease (60).
The underlying mechanism for reduced HDAC2 levels/
activities include post-translational modifications (i.e.,
nitrosylation, phosphorylation, and ubiquitination) leading to
proteasome-dependent degradation, particularly, in response
to CS (5, 43, 123), and/or oxidative/carbonyl modifications/
degradation of HDAC2 (178). HDAC2 is important for
the anti-inflammatory effects of glucocorticoid treatment.
The levels/activity of HDAC2 is decreased in lungs of
patients with COPD who are resistant to corticosteroid (60).
Corticosteroid resistance is also associated with increased
oxidative/carbonyl stress (aldehyde-mediated carbonylation
of proteins on cysteine, histidine, and lysine residues). Corti-
costeroids do not block the inflammatory response when
there is an increased oxidative stress, such as in severe asth-
matics and patients with COPD. This inefficacy is not asso-
ciatedwith alterations in nuclear HAT activity (60). Increasing
HDAC activity, by dietary polyphenol curcumin, sulfor-
aphane, or theophylline (HDAC2 activators), significantly en-
hances the steroid-induced suppression of IL-8 release in
monocytes and alveolar macrophage from COPD patients;
conversely, HDAC inhibitors have the opposing effects (30,
52, 85). This suggests a specific role of HDAC2 in steroid re-
sistance. Furthermore, deacetylation of glucocorticoid recep-
tor (GR) by HDAC2 enhanced the association of GR and
RelA/p65, which resulted in the attenuation of proin-
flammatory gene transcription in monocytes and lung cells
(61). Consequently, restoration or attenuation of decreased
HDAC2 levels/activities will further enhance the glucocorti-
coid sensitivity by deacetylating RelA/p65 and GR. This can
be achieved by reversing the post-translational modifications
of HDAC2, such as decarbonylation or dephosphorylation,
via inducing aldehyde dehydrogenases/reductases, thior-
edoxin reductase, and phosphatases, or inducing the
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FIG. 3. Classes of histone deacetylases (HDACs/SIRTs).
HDACs are classified into four distinct classes I to IV. Class I,
class II (subclasses: IIa and IIb), and class IV HDACs are
zinc-dependent enzymes, whereas class III HDACs that in-
cludes sirtuins (SIRTs: SIRT1–7) require nicotinamide ade-
nine dinucleotide (NAD+ ) for catalytic activity.
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antioxidant buffer systems by using Nrf2 activators and extra-
cellular superoxide dismutase mimetics (2, 183). Thus, HDAC2
is a redox-sensitive protein, whose levels/activities are de-
creased under oxidative/carbonyl stress conditions, resulting
in chromatin modifications associated with steroid resistance
leading to lung inflammation.
HDAC2, DNA damage/repair, and cellular senescence
CS/oxidants can also induce cellular senescence (i.e., stress-
induced premature senescence, SIPS) in alveolar epithelial
cells and fibroblasts, which is independent of telomere short-
ening (95, 101, 102, 155–157). Cellular senescence (irreversible
cell growth arrest) impairs the repair of damaged lung tissue,
perhaps, explaining why COPD progresses even after cessa-
tion of smoking. The role of cellular senescence in COPD is
supported by animal studies (74, 130, 137, 184), where CS is
known to cause premature senescence. The senescent cells are
metabolically active and prone to secrete proinflammatory
mediators (i.e., IL-6 and IL-8) and matrix metalloproteinases
(i.e., MMP-1, MMP-3, and MMP-9) (40, 125). These proin-
flammatory mediators may in turn initiate and maintain cel-
lular senescence as the deficiency of IL-6, IL-6R, or CXCR2
prevents premature senescence (1, 71). Indeed, the percentage
of proinflammatory senescent type II cells expressing both p16
and phosphorylated NF-jB (i.e., senescent-associated secre-
tory phenotype) was increased in lungs of patientswith COPD
as compared to smokers and nonsmokers (157). However, the
mechanism underlying premature senescence and associated
secretory senescence phenotype (secretory senescent cells) in
the development of COPD remains unknown.
Persistent DNA damage causes premature senescence and
senescence-associated secretory phenotype via forming per-
sistent foci, termed as DNA segments with chromatin alter-
ations reinforcing senescence (29, 125, 126). Further study
demonstrated the requirement of the upstream signals of
DNA damage response, including ataxia telangiectasia mu-
tated and its substrates Nijmegen breakage syndrome 1 and
checkpoint kinase 2 for the NF-jB-dependent inflammatory
phenotype in senescent cells (36, 125, 173). The double-strand
break is the most dramatic form of DNA damage, which can
be repaired either by homologous recombination, classical, or
alternative nonhomologous end joining. CS-mediated oxida-
tive stress has been shown to cause DNA damage, which is
increased in patients with COPD (21, 23, 33, 106, 134). The
nonhomologous end joining repair proteins, such as Ku70,
Ku80/Ku86, are also impaired by CS, which may, in turn,
accelerate the formation of persistent DNA segments with
chromatin alterations reinforcing senescence leading to sus-
tained DNA damage and an associated secretory senescence
phenotype observed in patients with COPD (21, 126, 135).
Ku70, Ku80/Ku86 proteins may be regulated by acetylation/
deacetylation. However, it is unclear how chromatin re-
modeling influences premature senescence and associated
secretory senescence phenotype during DNA damage/repair
by CS/oxidants in lung cells.
HDAC2, not only functions in DNA damage response to
promote repair, but also regulates cellular senescence and
inflammation via deacetylating histones and transcription
factors (e.g., NF-jB) (89, 150, 165, 169, 193). Indeed, histone
acetylation and methylation as well as NF-jB activation play
an important role in DNA damage repair and genomic in-
stability as well as premature aging (159, 190). Additionally,
other histone modifiers, such as CBP/p300, regulate DNA
damage and repair (103, 129, 163, 167). Cellular senescence
and its associated inflammatory phenotype occur in lungs of
patients with COPD (156, 157). It is evident that HDAC2
regulates cellular senescence along with its complex, such as
HDAC1, in response to stress (169). However, no information
is available regarding the role of HDAC2 epigenetic modifi-
cations in DNA damage/repair, as well as premature senes-
cence and associated secretory senescence phenotype,
particularly, in response to CS exposure in lung cells.
Histone modifications, including acetylation and methyl-
ation, play an important role in DNA damage repair and
genomic instability as well as premature aging (159, 163, 190).
It is possible that HDAC2 regulates CS-mediated DNA
damage, premature senescence, and associated secretory se-
nescence phenotype through histone deacetylation (Fig. 4).
HDAC2 can interact with protein methyltransferases to form
a large and multiple-protein complex(es), thereby regulating
transcriptional repression or activation (161). Our preliminary
studies have recently showed that CS exposure alters histone
methylation (e.g., H3K4me, H3K27me, H3K79me, H3K36ac/
me) in cells and mouse lung (27, 177). CS/oxidant-mediated
HDAC2 reduction may alter histone methylation by regulat-
ing enzyme methyltransferases. In addition to HDACs, CBP/
p300 also has shown to acetylate histone H3 and H4 at the
sites of DNA double-strand break, thereby regulating DNA
damage and repair (103, 163). HDAC2 interacts with CBP in
response to CS exposure (3). Therefore, other coactivators/
repressors, such as CBP/p300, andNF-jB alongwith HDAC2
participate in the CS-mediated DNA damage and premature
senescence and associated secretory senescence phenotype.
FIG. 4. Epigenetic regulation in cigarette smoke-mediated
persistent DNA damage leading to chronic obstructive lung
disease. Cigarette smoke-induced reduction in HDAC2/
SIRT1 and DNA damage response proteins, such as Ku70 and
Ku80, resulting in persistent DNA damage response. Cigarette
smoke also alters the expression levels of chromatin modifi-
cation enzymes, thus, affects epigenetic regulation of gene
expression due to site-specific histone modification in histone
H3 and H4. Persistent DNA damage further leads to stress-
induced premature senescence/senescence-associated secre-
tory phenotype, which subsequently causes premature aging
of the lung in pathogenesis of chronic obstructive pulmonary
disease (COPD) and smoking related disorders.
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SIRT1 deacetylase, FOXO3, NF-kB,
and cellular senescence
Sirtuin 1 (SIRT1) belongs to class III HDACs, which possess
anti-inflammatory, anti-aging/senescence, and anti-apopto-
tic/autophagy properties due to their ability to deacetylate
both histones and nonhistone proteins, including transcrip-
tion factors (e.g., NF-jB, FOXO3, p53, Ku70, and PGC-1a)
(182) (Fig. 5). SIRT1 levels and activities were decreased in
monocytes (MonoMac6 cells), bronchial epithelial cells (Beas-
2B), mouse lungs exposed to CS, as well as in the lungs of
COPD patients and smokers (54, 121, 122, 180), suggesting the
involvement of SIRT1 in the pathogenesis of COPD. The
mechanism for SIRT1 reduction involves post-translational
modifications, such as phosphorylation, nitrosylation, and
oxidation/carbonylation by ROS/carbonyls-aldehydes in re-
sponse to CS/oxidative/carbonyl stress, ultimately leading to
SIRT1 degradation (20, 121, 122). SIRT1 is also regulated by
the intracellular redox thiol (GSH/GSSG) pool (20, 180).
SIRT1 knockdown by siRNA leads to heightened NF-jB ac-
tivation and inflammatory response. SIRT1 activators, such as
SRT1720 and resveratrol diminished the release of proin-
flammatory mediators in response to oxidative stress/CS
exposure (122). These findings suggest a role for SIRT1 acti-
vators (90, 91) in the therapeutic intervention of COPD. Ad-
ministration of the SIRT1 activators, SRT2172 and SRT1720,
attenuated CS-induced lung inflammation in mice (96).
Furthermore, SIRT1-mediated protection in response to CS/
oxidative stress against lung inflammatory response and injury
are linked to the deacetylation of NF-jB RelA/p65 and
FOXO3, and negative regulation of MMP-9 via the tissue in-
hibitor of metalloproteinases-1 (25, 96, 180, 184). Further
studies are required to investigate the key molecular mecha-
nisms tounderstand howSIRT1 canmediate protection against
oxidative stress during COPD progression (184, 188).
SIRT1 also deacetylates other transcription factors, such as
FOXO3, p53, and NF-jB, thereby regulating CS/oxidative
stress-induced cell cycle arrest, apoptosis, and cellular se-
nescence, which play important roles in the pathogenesis of
COPD (Fig. 6) (188). Transcriptional activity of FOXO3 is
regulated by its phosphorylation and acetylation status.
SIRT1 deacetylates FOXO3, leading to its activation and to the
induction of cell cycle arrest, thereby reducing premature
senescence (94, 184, 189). FOXO3 is acetylated when SIRT1
levels/activity are reduced in response to CS in mouse lung
(121). Furthermore, FOXO3 has a regulatory role in lung in-
flammatory response and regulation of antioxidant genes,
such as manganese superoxide dismutase and catalase. Tar-
geted disruption of FOXO3 results in downregulation of these
antioxidant genes in mouse lungs and increases the suscep-
tibility for the development of COPD/emphysema (55). Yao
and colleagues have shown that the SIRT1-FOXO3-mediated
pathway is important in pathogenesis of COPD independent
of the NF-jB pathway (116, 184). Further studies on the
SIRT1-FOXO3 pathway will elucidate the underlying mech-
anisms in response to oxidative/carbonyl stress, and will
provide the possible therapeutic interventions in treatment of
COPD based on SIRT1 activation.
SIRT1 interacts with p53, and deacetylates lysine residue at
the C-terminal regulatory domain (162). Decreasing SIRT1
levels/activity increases p53 acetylation, thereby promoting
apoptosis and senescence (80, 162). Oxidative stress is shown
to accelerate cellular senescence, due to increased p53 acety-
lation via decreasing the function of SIRT1 through NAD +
depletion (42) (104). Furthermore, blocking p53 by antisense
oligonucleotides reversed the inhibitory effect of SIRT1 on
cellular senescence (104). Earlier studies have shown that the
nuclear levels of SIRT1 were decreased in response to CS
both in vitro and in vivo in lungs (180), but still it remains
unclear whether SIRT1-mediated regulation of p53 (acety-
lation/deacetylation) plays an important role in oxidants/
CS-mediated apoptosis, autophagy, and cellular senes-
cence/aging.
FIG. 5. SIRT1 as master regulator of chronic inflamma-
tion, aging/senescence, and apoptosis/autopahgy. SIRT1 is
a class III deacetylase that can deacetylate both histone and
nonhistone proteins, including transcription factors, such as
NF-jB, FOXO3, p53, p21, Ku70, and PGC1-a, thereby, reg-
ulating oxidative stress-induced chronic inflammation, cel-
lular senescence, apoptosis, and autophagy, which play key
roles in the pathogenesis of COPD. SIPS, stress-induced
premature senescence.
FIG. 6. Role of SIRT1, FOXO3, and NF-jB in oxidants/
cigarette smoke-mediated lung inflammation. Regulation of
SIRT1 activity by its substrate acetylated protein in presence
of NAD + will result in deacetylated protein, nicotinamide
and acetyl ADP-ribose molecules (Left panel). SIRT1 activity
and level are reduced by oxidative/carbonyl stress imposed
by cigarette smoke leading to RelA/p65 and FOXO3 acety-
lation (Right panel). This results in downregulation of anti-
oxidant genes, such as MnSOD and catalase, and NF-jB
activation via its interaction with CBP favoring expression of
proinflammatory and prosenescence genes.
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Other sirtuins have also been shown to modify cellular
functions under oxidative stress. For example, a recent report
demonstrated the role of SIRT6 in DNA repair under
oxidative stress through the activation of poly [adenosine
diphosphate-ribose] polymerase 1 (PARP1) (81). Oxidative
stress in mammalian cells recruits SIRT6 to the sites of DNA
double-strand breaks, where it interacts with PARP1 (redox
sensitive), andmono-ADP-ribosylates PARP1 on Lys521, thus
stimulating PARP1’s poly-ADP-ribosylase activity, and re-
pairing DNA double-strand break through both nonhomol-
ogous end joining and homologous recombination repair
mechanisms (81). Therefore, SIRT6, in addition to SIRT1 is
implicated to play crucial roles in oxidative stress-induced
inflammatory response, senescence, genomic instability,
DNA damage/repair, and aging (65, 81, 88, 158). Conse-
quently, other sirtuin members possibly gain equal credence
in understanding the pathogenesis of COPD and other
chronic lung diseases associated with tobacco smoking.
SIRT1 is a key regulator of vascular endothelial homeo-
stasis controlling angiogenesis, vascular tone, and endothelial
dysfunction by regulating the endothelial nitric oxide syn-
thase activity (109, 172). Endothelial dysfunction plays an
important role in pathogenesis of emphysema, and CS-
induced emphysematous alveolar destruction, which is
almost avascular, associated with decreased expression of
endothelial nitric oxide synthase (35, 38). SIRT1 deacetylates
lysines at position K496 and K506 in the calmodulin-binding
domain of endothelial nitric oxide synthase, leading to
enhanced nitric oxide production, which is vital for endo-
thelial-dependent vasorelaxation, cell survival, migration,
and postnatal neovascularization (10, 84). NO activates the
SIRT1 promoter, thereby increasing SIRT1mRNAand protein
levels (100, 105), suggesting that a positive feedback mecha-
nism exists between SIRT1 and endothelial nitric oxide
synthase (110). Therefore, the activation of SIRT1 by small
molecules (such as SRT1720) may help in resetting the endo-
thelial nitric oxide synthase activity during endothelial dys-
function in patients with COPD, where NO availability is
limited (87). SIRT1 overexpression attenuated CS-induced
apoptosis and inflammatory response in cultured coronary
arterial endothelial cells (31). Therefore, SIRT1 acts as a pos-
sible epigenetic chromatin redox regulator in the treatment
and prevention of chronic lung diseases, including COPD and
comorbidities associated with endothelial dysfunction and
cardiovascular problems by protecting endothelial cells from
stress-induced premature senescence, autophagy, apoptosis,
and inflammatory response.
Histone methyltransferase
Methylation of histones occurs either on lysine (K) or argi-
nine (R) residues in a reaction that is catalyzed by specific
HMTs (PRMT family, the SET-domain [Suppressor of varie-
gation-Enhancer of zeste-Trithorax domain]-containingprotein
and the non-SET-domain proteins DOT1/DOT1L) (11,192).
HMTs utilize S-adenosylmethionine as a cofactor during
transmethylation and produce S-adenosylhomocysteine as a
by-product. The substrate specificity and activity of HMT de-
pends on SET domains and associated motifs (191). Methyla-
tion of specific lysine residues results in the formation of
binding sites/interacting domains, which allow recruitment of
other regulator proteins (coactivators/corepressors). HMTs are
deregulated in several chronic lung diseases, thereby affecting
the global methylation status. Histone H3K4, H3K9, and
H3K27, and H4K20 are frequently and preferentially methyl-
ated asmono-, di-, or tri-methylated histoneH3 and histoneH4
(131). Methylation at H3K4, H3K36, and H3K79 is linked to
gene activation, whereas H3K9, H3K20, and H3K27 methyla-
tion is associated with gene repression (49) (Fig. 7).
Histone modifications are regulated by specific chromatin
modification enzymes, which have a residue-specific role in
regulating gene expression with respect to histone modifica-
tions (9, 19, 68, 127). In vitro exposure of airway epithelial cells or
immortalized bronchial epithelial cells to CS condensate/
extract (oxidants) reduced H4K16ac and H4K20me3, but in-
creased H3K27me3. This may have implications in tumor
development in several cancer types associated with tobacco
smoking (77). It is well known that COPD is associated with a
significantly increased incidence of lung cancer and other co-
morbidities in susceptible chronic smokers. HDACs, including
HDAC2 and SIRT1, play an important role in cancer cell epi-
genetic regulation and gene expression. Histone H4K16ac and
H4K20me3 has been suggested as a hallmark in different kinds
of human tumors and tumor-derived cell lines, thus character-
ized as known epigenetic marks in cancer (39). SIRT1 depletion
by siRNA in mammalian cells resulted in hyperacetylation of
histone H4K16 and decreased H3K9me3 and H4K20me3 (160).
However, it remains to be seen whether the regulation of these
enzymes and specific histone modifications via modulation by
oxidative stress and/or redox status of the cells also occur in
redox epigenetic chromatin regulation of proinflammatory
genes in COPD and smoking-induced diseases.
The cross-talk between histone methylation sites also con-
trols the transcriptional activation of target genes (26, 168).
The positive and negative cross talk, ultimately, generates the
FIG. 7. Redox-mediated chromatin modifications in
chronic inflammation and cellular senescence. Cigarette
smoke-derived oxidants/carbonyls can activate various re-
dox signaling cascades, thereby, leading to histone modifi-
cations on proinflammatory gene promoters. Histone
modifications can cross talk with CpG methylation to acti-
vate or repress gene transcription. Modulation of various
genes due to specific histone acetylation/methylation can
result in inflammation and cellular senescence observed in
chronic lung inflammatory diseases. Some of the known
methylation and acetylation histone marks that either cause
gene repression (H3K27me3 and H3K9me2/3) or gene acti-
vation (H3K9ac, H3K14ac, H3K4me3, H3K36me3, H3K79me3,
H4K20me) are summarized.
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complex pattern of gene- or locus-specific histone marks,
which are linked with distinct chromatin states (euchromatin
or heterochromatin), leading to transcriptional repression or
activation. Cross-talk exists between various epigenetic events
on histones and DNA methylation (Fig. 7). For example, the
methylcytosine-binding protein recruits HDACs to methyl-
ated DNA as well as to methylated histones. These events are
associated with histone deacetylation and chromatin con-
densation, leading to transcriptional silencing of genes (47,
98). On the contrary, inhibition of HDACs and histone
acetylation/methylation leads to upregulation of proin-
flammatory mediators, such as the granulocyte–macrophage
colony-stimulating factor by IL-1b in lung epithelial cells (63).
Although histone H3K4 tri-methylation has been reported
to play a role in tumorigenesis and X-chromatin inactivation
in human cells (73), little evidence is available for its role in
inflammatory responses. Furthermore, hypermethylation of
histone H3K4 was found to be unrelated to acute TNF-a-
induced gene expression (128). In contrast, the involvement of
H3K4 tri-methylation in IL-1b-induced gene expression has
been reported (164). Furthermore, H3K4 tri-methylation plays
a critical role in IL-1b stimulated secretory leukocyte protease
inhibitor expression by modulating RNA polymerase II re-
cruitment, and subsequent engagement of SET1 (164). Con-
versely, very few reports are available on cross-talk between
histone acetylation and methylation in response to CS/oxi-
dative stress-mediated lung inflammation and in pathogene-
sis of chronic inflammatory lung diseases. Studies on
sequential events of histone acetylation/histone methylation
will provide the understanding on the new epigenetics-based
biomarkers and/or treatment for chronic inflammatory dis-
eases, including COPD (Fig. 7).
Histone demethylases
HDMs catalyze the removal of methyl groups from lysine
or arginine residue of histones. They are classified into two
types, the lysine-specific demethylase 1 and JmjC domain
family proteins involved in the regulation of gene expression
(149). Lysine-specific demethylase 1 specifically demethylates
histone H3K4me2, and is an important member of HDMs
among other transcriptional repression complexes (133).
Lysine-specific demethylase 1 utilizes oxygen as an electron
acceptor to reduce methylated lysine to form lysine, formal-
dehyde, and hydrogen peroxide (133). JmjC demethylates
mono-, di-, or trimethyl lysine residues by a different mech-
anism that requires cofactors, such as molecular oxygen, a-
ketoglutarate, Fe2 + , and ascorbate via a redox modulating
process (66, 67). Aberrant expression of HDMs occurs during
the course of tumor initiation and progression (76) possibly
due to increased oxidative stress. However, the role of ROS/
redox GSH status in modulation of HDMs in COPD and other
chronic lung diseases remains unknown.Hypoxia is known to
occur in tumor microenvironments, as well as in lungs of
patients with COPD. The level of lysine-specific demethylase
4B is upregulated in response to hypoxia, which depends on
hypoxia-inducible factor 1 alpha (176). Inhibition of H3K4
demethylase ( JmjC domain-containing histone demethyla-
tion protein 1A) reduces tumor growth in vivo demonstrating
its role in regulating histone methylation in hypoxia. Fur-
thermore, induction of JmjC domain-containing histone de-
methylation protein 1A by hypoxia-inducible factor 1 alpha
acts as an epigenetic signal amplifier to enhance hypoxic gene
expression, thus facilitating tumor growth (70). In contrast,
hypoxia increases global levels of H3K4me3 in alveolar A549
and bronchial Beas-2B cell lines, due to the inhibition of
demethylation process, particularly, demethylase (Lysine-
specific demethylase 5A). Therefore, hypoxia targets lysine-
specific demethylase 5A, which induces H3K4me3 both
globally and at gene-specific promoters (heme oxygenase-1
and decay-accelerating factor), thus promoting alterations in
the pattern of gene expression and tumor progression (194).
Understanding the molecular epigenetic mechanism that in-
volves HDMs in COPD/lung cancer will influence treatment
options and outcomes in COPD, lung cancer, and other
chronic lung diseases associated with tobacco smoking (139).
DNA Methylation
DNA methylation is a nonhistone epigenetic event that
plays an important role in transcriptional regulation, for ex-
ample, gene silencing. Methylation occurs on cytosine resi-
dues, producing 5-meC (5-methylcytosine) (142). DNA
methylation is associated with epigenetic silencing, and this
effect is, in part, mediated by recruitment of HDACs through
the methyl-DNA-binding motifs, including components of
several HDAC-containing complexes (97). Environmental
factors/agents that trigger oxidative stress, such as diet, ge-
netic predisposition factors, and aging can gradually affect
the promoter CpG methylation by recruiting methyl CpG-
binding protein 2 and DNA methytransferases to various
promoters along with HDACs. This leads to alterations in the
expression of tumor suppressor, onocogenes, and pro- and
anti-inflammatory genes. Gene-silencing occurs in several
genes (e.g., GDNF, MTHFR, OPCML, TNFRSF25, TCF21,
PAX8, PTPRN2, and PITX2) due to promoter-specific hy-
permethylation in lung cancer (7, 12). However, the relation-
ship between gene-specific DNA methylation and smoking
history/disease progression is not known (154). Georgiou
et al. reported methylation of the p16 promoter in sputum of
patients with COPD that significantly correlated with heavy
cigarette smoking, suggesting DNAmethylation is associated
with CS/oxidant-mediated lung diseases (45). Array-based
methylation screening from two family-based cohorts
(n= 1,085 and 396 subjects) revealed 349 CpG sites signifi-
cantly associated with the presence and severity of COPD.
Significant association was shown between SERPINA1 hy-
pomethylation and pathogenesis of COPD with lower lung
function. Similarly, Philibert et al. have recently shown that
smoking altered DNA methylation in alveolar macrophages
correlates with vascular endothelial growth factor 1 gene ex-
pression (107). This implicates that DNA methylation/hypo-
methylation that is caused by oxidative stress in specific genes
may be an epigenetic event in pathogenesis of COPD (111).
CS affects DNAmethylation on several genes on their CpG
island directly or indirectly. CS downregulates DNA me-
thyltransferase 3B in alveolar A549 epithelial cells resulting in
demethylation of the CpG island in the oncogene synuclein-
gamma and leading to high expression of this prometastatic
oncogene in A549 cells (78). Sood et al. identified the promoter
methylation from sputum samples of patients demonstrating
wood smoke (biomass fuel burning) exposure associatedwith
the COPD phenotype (decline in lung function, airflow ob-
struction, and chronic bronchitis), and smokers with aberrant
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p16 and GATA binding protein 4 methylation (136). It would
be interesting to conduct studies on identifying epigenetic
changes in DNA isolated from chronic CS or biomass/wood
smoke exposed mouse lungs to identify the genes that are
specifically modified by CS and/or biomass/wood smoke
exposure that can be used as better biomarkers in smoke-
mediated chronic lung diseases. Suzuki et al. demonstrated
methylation of IL-12Rb2 andWnt inhibitory factor-1 in COPD
patients compared to the non-COPD group, suggesting the
molecular epigenetic events that influence COPD-related
nonsmall cell lung cancer 141). Another report described the
association of prenatal exposure to tobacco smoke with sig-
nificant changes in two types of DNA methylation (global
methylation and promoter CpG island methylation) (18).
Furthermore, children exposed to second-hand tobacco
smoke had a lower methylation profile of their AluYb8 re-
petitive elements compared to unexposed children. Genetic
susceptibility plays a vital role in smoking related effects
based on differences in gene variants (methylation of LINE1
with the common GSTM1 null genotype and CpG-specific
methylation with a common GSTP1 haplotype) among
children involved in detoxification of tobacco smoke. This
supports that epigenetic effects of in utero exposures may be
due to alterations in DNA methylation patterns (18). Co-
ordinated changes in DNA methylation, particularly, at the
aryl hydrocarbon receptor repressor was observed in lym-
phoblasts and alveolar macrophages from smokers sug-
gesting the role of epigenetic effects mediated by CS on
carcinogenesis and other related comorbidities (92). The
DNA methylation status on susceptibility genes may have
implications in smokers, who are at high risk for COPD de-
velopment. These studies suggest that DNA methylation
may play an important role in the regulation of proin-
flammatory response. The role of various histone modifica-
tions versus promoter DNA methylation, particularly, in
response to oxidative stress in inflammatory conditions, and
in pathogenesis of COPD and other smoking related airway
diseases is an emerging field of further research.
Translational Impact of Chromatin Remodeling
in COPD and Smoking Related Diseases
COPD is predominantly a tobacco smoke-triggered disease
characterized by premature lung aging and steroid resistance,
which is, in part, due to CS-mediated chromatin modifica-
tions. The translational impact of chromatin remodeling in the
pathogenesis of COPD and other smoking related diseases is
as follows: (i) CS-mediated ROS production activates various
kinases leading to histone acetylation and chromatin re-
modeling on proinflammatory genes. Inhibition of HATs by
small molecule inhibitors would inhibit lung inflammation.
(ii) HDAC2 reduction is associated with steroid resistance in
the inflammatory response by CS-mediated oxidative stress.
Activation of HDAC2 by theophylline and curcumin would
reverse steroid resistance, and hence, provide protection
against lung inflammatory response. (iii) SIRT1 undergoes
oxidative/carbonyl post-translational modifications leading
to degradation in response to CS. SIRT1 regulates several bi-
ological processes via FOXO3 and NF-jB-dependent mecha-
nisms, which are involved in lung inflammaging. Activation
of SIRT1 by pharmacological agents would protect lung
cells against premature senescence and inflammaging. (iv)
HDAC2-dependent epigenetic mechanism may be associated
with DNA damage-induced premature senescence and asso-
ciated secretory senescence phenotype in response to oxida-
tive stress imposed by smoke. (v) CS/oxidative stress causes
DNA damage, which is increased in patients with COPD/
emphysema. Persistent DNA damage can lead to premature
senescence with increased proinflammatory mediators release
by secretory senescent cells via formingpersistentDNAdamage
foci, termed as DNA segments with chromatin alterations re-
inforcing senescence (distinct nuclear structures that sustain
damage-induced senescence growth arrest and inflammatory
cytokine secretion). (vi) Chromatin remodeling, including his-
tone modifications (e.g., histone acetylation/deacetylation and
methylation/demethylation) are shown to regulate cellular
senescence. Histone acetylation and NF-jB-dependent proin-
flammatory cytokines are increased in CS-exposed rodent lungs
and in lungs of patients with COPD. Histone modifications are
associated with DNA damage/repair and epigenomic insta-
bility as well as premature lung aging, which has implications
in pathogenesis of COPD. The chromatinmodification enzymes
responsible for histone methylation/demethylation and acety-
lation/deacetylation (e.g., HDACs) also regulate cellular se-
nescence and aging. Overall, reversing the CS-induced aberrant
chromatinmodifications on proinflammatory and prosenescent
genes would have effects on attenuating the premature lung
aging in the progression of COPD.
Conclusions and Future Directions
Oxidative stress by CS/oxidants is critical for the chronic
lung inflammatory response via activation of stress kinases,
redox-sensitive transcription factors, and modulation of epi-
genetic chromatin modifications, which result in gene tran-
scription. Recent studies have focused on identifying genes
that undergo epigenetic modifications; it is increasingly im-
portant to better understand the molecular mechanism that
controls the overall epigenetic state of a cell, particularly, in
response to environmental stresses. Another key area that will
gain more importance is to understand whether these histone
modifications enzymes, such as HATs/HDACs and HMTs/
HDMs share any common targets, so as to design a common
therapeutic agent. Recent studies have highlighted the phar-
macological significance ofHDACs and SIRT1 in regulation of
lung inflammation. Identification of specific substrates/mol-
ecules targeted by HDACs and SIRT1 may have considerable
Innovation
Epigenetic/chromatin modifications are involved in
inflammation, cellular senescence, and steroid resistance
caused by cigarette smoke (CS)-induced oxidative stress.
CS and oxidants provoke specific histone modifications in
lungs of patients with chronic obstructive pulmonary
disease (COPD), which are associated with DNA damage
response/impaired DNA repair, epigenomic instability,
and premature lung aging. Reduction in HDAC2 is asso-
ciated with inflammatory response, steroid resistance, and
senescence in lung cells. Understanding themechanisms of
CS/oxidative stress-mediated chromatin modifications
and cellular senescence will lead to identification of po-
tential therapeutic targets for interventions in COPD and
CS-related diseases.
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therapeutic implications against chronic inflammatory lung
diseases. Histone acetylation and deacetylation, as well as
histone/DNA methylation play an important role in oxida-
tive stress-induced chronic inflammatory diseases, such as
asthma, COPD, and other smoking induced diseases. HDAC2
is required for glucocorticoids to function as anti-inflamma-
tory agents. The level/activity of HDAC2 is reduced in in-
flammatory cells and lungs of patients with severe asthma and
COPD (114, 187). Activation ofHDAC2 or reversal of oxidative
post-translational modifications of HDAC2 is another avenue
to devise epigenetic-based therapy in treatment of severe
asthma and COPD. Thus, understanding the molecular
epigenetic redox regulation mechanisms will enable the de-
velopment of newer epigenetic-based therapeutic strategies in
the treatment of chronic inflammatory lung diseases.
Cross-talk exists between various epigenetic markers on
histones and DNA methylation. Future studies will help to
understand the extent to which these post-translational
modifications, which are regulated by ROS in inflammation
and steroid resistance, are linked to chronic inflammatory
lung diseases associated with cigarette smoking. Studies on
ROS and redox epigenetic regulation will further unravel the
mechanisms and identify possible epigenetics-based thera-
pies for chronic inflammatory diseases, particularly, COPD
and smoking induced diseases.
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Abbreviations Used
CBP¼CREB-binding protein
COPD¼ chronic obstructive pulmonary disease
CS¼ cigarette smoke
FOXO3¼ forkhead box O3
GR¼ glucocorticoid receptor
GSH¼ glutathione
HAT¼histone acetyltransferase
HDAC¼histone deacetylase
HDM¼histone demethylase
HMT¼histone methytransferase
JNK¼ c-Jun N-terminal kinase
NF-jB¼nuclear factor jB
PI3K¼phosphoinositide 3-kinase
PKC¼protein kinase C
ROS¼ reactive oxygen species
SIPS¼ stress-induced premature senescence
SIRT1¼ sirtuin 1
TSA¼ trichostatin A
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